# Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes

DOI: 10.1038/sj.ejcn.1601464
European Journal of Clinical Nutrition, 2002, 56, 1137-42.

| # | Paper | IF | Citations |
|---|---|---|---|
| 211 | Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. **2003**, 18, 91-100 | | 104 |
| 210 | Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. **2003**, 18, 129-36 | | 23 |
| 209 | Oxidative stress: the special case of diabetes. **2003**, 19, 11-8 | | 40 |
| 208 | Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. **2003**, 168, 169-79 | | 72 |
| 207 | Coenzyme Q10: One Antioxidant, Many Promising Applications. **2003**, 9, 111-116 | | 4 |
| 206 | Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the ?recoupling hypothesis? **2004**, 97, 537-48 | | 96 |
| 205 | Update on lifestyle and hypertension control. **2004**, 26, 739-46 | | 3 |
| 204 | Physiology: orphan detectors of metabolism. **2004**, 429, 143-5 | | 37 |
| 203 | The role of antioxidant micronutrients in the prevention of diabetic complications. **2004**, 3, 41-52 | | 87 |
| 202 | Biological validation of coenzyme Q redox state by HPLC-EC measurement: relationship between coenzyme Q redox state and coenzyme Q content in rat tissues. **2004**, 578, 53-7 | | 35 |
| 201 | Metabolism and function of coenzyme Q. **2004**, 1660, 171-99 | | 701 |
| 200 | Simultaneous determination of coenzyme Q10, cholesterol, and major cholesterylesters in human blood plasma. **2004**, 378, 162-9 | | 9 |
| 199 | Role of oxidative modifications in atherosclerosis. **2004**, 84, 1381-478 | | 1918 |
| 198 | Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10?. **2005**, 23, 7-14 | | 17 |
| 197 | Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. **2005**, 4, 5 | | 568 |
| 196 | Factors regulating isoprostane formation in vivo. **2005**, 7, 221-35 | | 100 |
| 195 | Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. **2005**, 68, 207-16 | | 36 |

| | | |
|---|---|---|
| 194 | Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. **2005**, 37, 1208-18 | 156 |
| 193 | Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. **2005**, 59, 312-7 | 14 |
| 192 | Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. **2005**, 65, 31-74 | 57 |
| 191 | Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. **2005**, 45, 185-97 | 352 |
| 190 | Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. **2006**, 40, 445-53 | 340 |
| 189 | Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study. **2006**, 187, 198-204 | 21 |
| 188 | The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. **2006**, 12, 464-72 | 124 |
| 187 | Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial. **2006**, 35, 30-7 | 19 |
| 186 | Oxidative Stress and Coenzyme Q10 Therapy. **2006**, 965-993 | |
| 185 | Use of Biomarkers of Oxidative Stress in Human Studies. **2006**, 1045-1076 | 1 |
| 184 | Supplemental conditionally essential nutrients in cardiovascular disease therapy. **2006**, 21, 9-16 | 25 |
| 183 | Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q(10). **2006**, 23, 1344-9 | 48 |
| 182 | Oxidative stress and cardiovascular disease: antioxidants and unresolved issues. **2005**, 23, 115-32 | 66 |
| 181 | Risk assessment for coenzyme Q10 (Ubiquinone). **2006**, 45, 282-8 | 63 |
| 180 | Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice. **2006**, 40, 480-7 | 95 |
| 179 | Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus. **2006**, 26, 447-51 | 5 |
| 178 | A rapid and sensitive LC-MS/MS method for determination of coenzyme Q10 in tobacco (Nicotiana tabacum L.) leaves. **2006**, 29, 1607-12 | 16 |
| 177 | Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. **2006**, 91, 4737-42 | 25 |

| | | |
|---|---|---|
| 176 | Algorithm for complementary and alternative medicine practice and research in type 2 diabetes. **2007**, 13, 159-75 | 24 |
| 175 | [Oxidative stress and atherosclerosis]. **2007**, 127, 1997-2014 | 28 |
| 174 | Improvement in intestinal coenzyme q10 absorption by food intake. **2007**, 127, 1251-4 | 45 |
| 173 | Measurement of coenzyme Q10 in clinical practice. **2007**, 384, 180-1 | 8 |
| 172 | Coenzyme Q10 in cardiovascular disease. **2007**, 7 Suppl, S154-67 | 104 |
| 171 | Discovery of ubiquinone (coenzyme Q) and an overview of function. **2007**, 7 Suppl, S2-7 | 96 |
| 170 | The clinical application of metabolic therapy for cardiovascular disease. **2007**, 16 Suppl 3, S56-64 | 7 |
| 169 | Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. **2007**, 21, 297-306 | 167 |
| 168 | Rapid neonatal weight gain in rats results in a renal ubiquinone (CoQ) deficiency associated with premature death. **2007**, 128, 681-7 | 21 |
| 167 | Current prospects for the production of coenzyme Q10 in microbes. **2007**, 25, 514-21 | 72 |
| 166 | Metabolic syndrome in drug abuse. **2007**, 1122, 50-68 | 24 |
| 165 | The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline. **2008**, 31, 938-44 | 5 |
| 164 | Preparative Purification of Solanesol from Tobacco Leaf Extracts by Macroporous Resins. **2008**, 31, 87-94 | 25 |
| 163 | Mathematical Analysis of Solanesol Adsorption on Macroporous Resins using the General Rate Model. **2008**, 31, 1310-1318 | 8 |
| 162 | Equilibrium, thermodynamics and breakthrough studies for adsorption of solanesol onto macroporous resins. **2008**, 47, 1420-1427 | 30 |
| 161 | Antioxidant level and redox status of coenzyme Q10 in the plasma and blood cells of children with diabetes mellitus type 1. **2008**, 9, 540-5 | 23 |
| 160 | Supplementation of coenzyme Q10 and alpha-tocopherol lowers glycated hemoglobin level and lipid peroxidation in pancreas of diabetic rats. **2008**, 28, 113-21 | 37 |
| 159 | The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. **2008**, 22, 832-9 | 31 |

| | | |
|---|---|---|
| 158 | F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. **2008**, 10, 1405-34 | 214 |
| 157 | Interaction of coenzyme Q10 with the intestinal drug transporter P-glycoprotein. **2008**, 56, 6923-7 | 23 |
| 156 | Una mirada selectiva a las interacciones entre fármacos y medicina natural. **2009**, 1095-1103 | |
| 155 | Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. **2009**, 16, 4654-67 | 115 |
| 154 | Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. **2009**, 16, 94-112 | 204 |
| 153 | Oxidative stress, endothelial dysfunction and atherosclerosis. **2009**, 15, 2988-3002 | 185 |
| 152 | Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. **2009**, 124, 259-68 | 143 |
| 151 | Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression. **2009**, 240, 377-84 | 80 |
| 150 | Acute, subacute toxicity and genotoxic effect of Bio-Quinone Q10 in mice and rats. **2009**, 53, 1-5 | 15 |
| 149 | Assembly of Coenzyme Q10 nanostructure resembling nascent discoidal high density lipoprotein particle. **2009**, 388, 217-21 | 8 |
| 148 | Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. **2009**, 18, 11-8 | 37 |
| 147 | Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. **2009**, CD007435 | 29 |
| 146 | Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic control. **2009**, 20, 248-51 | 23 |
| 145 | The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. **2009**, 27, 1863-72 | 64 |
| 144 | Renal protective effect of metabolic therapy in patients with coronary artery disease and diabetes: from bench to bed side. **2009**, 15, 863-82 | 9 |
| 143 | Diabetes and antioxidants: myth or reality?. **2010**, 8, 661-72 | 19 |
| 142 | Scientific Opinion on the substantiation of health claims related to coenzyme Q10 and contribution to normal energy-yielding metabolism (ID 1508, 1512, 1720, 1912, 4668), maintenance of normal blood pressure (ID 1509, 1721, 1911), protection of DNA, prote. **2010**, 8, 1793 | 7 |
| 141 | Pharmacokinetic Interaction between Nifedipine and Coenzyme Q10 in Rats: A New Type of Drug-Supplement Interaction. **2010**, 56, 310-320 | 4 |

| | | |
|---|---|---|
| 140 | Current state of coenzyme Q(10) production and its applications. **2010**, 85, 1653-63 | 53 |
| 139 | Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. **2010**, 7, 55 | 60 |
| 138 | Recovery of solanesol from tobacco as a value-added byproduct for alternative applications. **2010**, 101, 1091-6 | 21 |
| 137 | Grapefruit juice enhance the uptake of coenzyme Q10 in the human intestinal cell-line Caco-2. **2010** , 120, 552-555 | 12 |
| 136 | Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study. **2010**, 6, 513-8 | 23 |
| 135 | Complementary and Alternative Medicine Therapies for Diabetes: A Clinical Review. **2010**, 28, 147-155 | 35 |
| 134 | Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. **2010**, 19, 535-54 | 93 |
| 133 | Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. **2011**, 214, 422-5 | 17 |
| 132 | Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. **2011**, 216, 395-401 | 73 |
| 131 | Micronutrient Metabolism in Hemodialysis Patients. **2011**, | 2 |
| 130 | The Starving Cell: Metabolic Syndrome as an Adaptive Process. **2011**, | 0 |
| 129 | Identification of bottlenecks in Escherichia coli engineered for the production of CoQ(10). **2011**, 13, 733-44 | 47 |
| 128 | Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. **2011**, 32, 6860-74 | 121 |
| 127 | Coenzyme Q(10) , endothelial function, and cardiovascular disease. **2011**, 37, 366-73 | 39 |
| 126 | Enhancement of antibody production by the addition of Coenzyme-Q(10). **2011**, 63, 163-70 | 6 |
| 125 | Postprandial antioxidant effect of the Mediterranean diet supplemented with coenzyme Q10 in elderly men and women. **2011**, 33, 579-90 | 43 |
| 124 | Coenzyme Q10 suppresses oxLDL-induced endothelial oxidative injuries by the modulation of LOX-1-mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway. **2011**, 55 Suppl 2, S227-40 | 75 |
| 123 | Solanesol: added value from Solanaceous waste. **2011**, 72, 1323-7 | 31 |

| | | |
|---|---|---|
| 122 | Antioxidants in the treatment of diabetes. **2011**, 7, 106-25 | 126 |
| 121 | Preparation of Nano-Coenzyme Q10 by Water Jet Comminution. **2011**, 110-116, 3791-3794 | |
| 120 | A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. **2012**, 25, 261-70 | 42 |
| 119 | Herbal, vitamin, and mineral supplement use in patients enrolled in a cardiac rehabilitation program. **2012**, 32, 270-7 | 4 |
| 118 | Dietary supplements and probiotics for diabetes. **2012**, 112, 47-53 | 8 |
| 117 | The production of coenzyme Q10 in microorganisms. **2012**, 64, 303-26 | 14 |
| 116 | Is there a place for coenzyme Q in the management of metabolic disorders associated with obesity?. **2012**, 70, 631-41 | 17 |
| 115 | The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. **2012**, 26, 352-8 | 23 |
| 114 | The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. **2012**, 38, 416-21 | 29 |
| 113 | Adjunctive naturopathic care for type 2 diabetes: patient-reported and clinical outcomes after one year. **2012**, 12, 44 | 23 |
| 112 | Reprogramming Microbial Metabolic Pathways. **2012**, | 5 |
| 111 | Effects of coenzyme Q10 and Ɛlipoic acid supplementation in fructose fed rats. **2012**, 50, 145-51 | 7 |
| 110 | Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. **2012**, 55, 1544-53 | 100 |
| 109 | Nutraceuticals as therapeutic agents for holistic treatment of diabetes. **2013**, 7, 278 | 4 |
| 108 | Dietary Supplements for Diabetes Are Decidedly Popular: Help Your Patients Decide. **2013**, 26, 259-266 | 5 |
| 107 | Prophylactic and antinociceptive effects of coenzyme Q10 on diabetic neuropathic pain in a mouse model of type 1 diabetes. **2013**, 118, 945-54 | 40 |
| 106 | Systematic review of the effect of coenzyme Q10 on antioxidant capacity while focused on evaluation of claims for health functional food. **2013**, 46, 218 | 6 |
| 105 | Novel CoQ10 antidiabetic mechanisms underlie its positive effect: modulation of insulin and adiponectine receptors, Tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats. **2014**, 9, e89169 | 41 |

| | | |
|---|---|---|
| 104 | Clinical applications of coenzyme Q10. **2014**, 19, 619-33 | 68 |
| 103 | Dietary supplements in the management of hypertension and diabetes - a review. **2014**, 11, 248-58 | 9 |
| 102 | Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials. **2014**, 15, 20169-208 | 16 |
| 101 | Coenzyme q10 therapy. **2014**, 5, 187-97 | 85 |
| 100 | Co-enzyme Q10. **2014**, 31, 173-174a | |
| 99 | Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. **2014**, 45, 589-95 | 58 |
| 98 | Stabilization of aqueous dispersion of CoQ10 nanoparticles using maize starches. **2014**, 35, 144-149 | 11 |
| 97 | Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. **2014**, 142, 375-415 | 354 |
| 96 | Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial. **2014**, 13, 81 | 35 |
| 95 | Effect of Coenzyme Q10 supplementation on antioxidant enzymes activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial. **2014**, 46, 177-83 | 80 |
| 94 | n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease. **2015**, 33, 1947-53 | 20 |
| 93 | Supplementation of Coenzyme Q10 among Patients with Type 2 Diabetes Mellitus. **2015**, 3, 296-309 | 27 |
| 92 | Coenzyme Q10 remarkably improves the bio-energetic function of rat liver mitochondria treated with statins. **2015**, 762, 270-4 | 19 |
| 91 | Solanesol: a review of its resources, derivatives, bioactivities, medicinal applications, and biosynthesis. **2015**, 14, 403-417 | 34 |
| 90 | Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis. **2015**, 40, 413-8 | 50 |
| 89 | Microalgae as a source of nutraceuticals. **2015**, 255-291 | 7 |
| 88 | Glutaredoxin mediated redox effects of coenzyme Q10 treatment in type 1 and type 2 diabetes patients. **2015**, 4, 14-20 | 16 |
| 87 | Advancing beyond the "heart-healthy diet" for peripheral arterial disease. **2015**, 61, 265-74 | 22 |

| | | |
|---|---|---|
| 86 | Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?. **2015**, 17, 472 | 25 |
| 85 | Coenzyme Q10 Supplementation Prevents Iron Overload While Improving Glycaemic Control and Antioxidant Protection in Insulin-Resistant Psammomys obesus. **2016**, 173, 108-15 | 4 |
| 84 | Automated statistical experimental design approach for rapid separation of coenzyme Q10 and identification of its biotechnological process related impurities using UHPLC and UHPLC-APCI-MS. **2016**, 39, 3528-35 | 2 |
| 83 | Additive enhancement of wound healing in diabetic mice by low level light and topical CoQ10. **2016** , 6, 20084 | 24 |
| 82 | Ubidecarenone (ubiquinone). **2016**, 237-240 | |
| 81 | Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. **2016**, 3, CD007435 | 13 |
| 80 | Regenerative Medicine for Degenerative Muscle Diseases. **2016**, | |
| 79 | Practical Nutrition Guidelines for Individuals with Duchenne Muscular Dystrophy. **2016**, 225-279 | 1 |
| 78 | The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome. **2016**, 55, 2357-2364 | 56 |
| 77 | Amelioratory effect of coenzyme Q10 on potential human carcinogen Microcystin-LR induced toxicity in mice. **2017**, 102, 176-185 | 19 |
| 76 | PEGylated Solanesol for Oral Delivery of Coenzyme Q. **2017**, 65, 3360-3367 | 17 |
| 75 | The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. **2017**, 86, 560-566 | 27 |
| 74 | Levetiracetam synergizes with gabapentin, pregabalin, duloxetine and selected antioxidants in a mouse diabetic painful neuropathy model. **2017**, 234, 1781-1794 | 6 |
| 73 | A meta-analysis of randomized and placebo-controlled clinical trials suggests that coenzyme Q10 at low dose improves glucose and HbA1c levels. **2017**, 38, 1-12 | 9 |
| 72 | Integration of heterologous 4-hydroxybenzoic acid transport proteins in Rhodobacter sphaeroides for enhancement of coenzyme Q10 production. **2017**, 7, 17346-17352 | 8 |
| 71 | The Effect of Coenzyme Q10 Supplementation on Circulating Levels of Novel Adipokine Adipolin/CTRP12 in Overweight and Obese Patients with Type 2 Diabetes. **2017**, 125, 156-162 | 14 |
| 70 | Self-Nanoemulsifying Drug Delivery System of Coenzyme (Q10) with Improved Dissolution, Bioavailability, and Protective Efficiency on Liver Fibrosis. **2017**, 18, 1657-1672 | 29 |
| 69 | Targeting Complications of Diabetes with Antioxidants. **2017**, 397-445 | 1 |

| | | |
|---|---|---|
| 68 | An update on diabetic kidney disease, oxidative stress and antioxidant agents. **2017**, 6, 153-157 | 35 |
| 67 | Insulin- and quercetin-loaded liquid crystalline nanoparticles: implications on oral bioavailability, antidiabetic and antioxidant efficacy. **2018**, 13, 521-537 | 20 |
| 66 | The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials. **2018**, 25, 41-50 | 22 |
| 65 | Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials. **2018**, 132, 232-241 | 18 |
| 64 | Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?. **2018**, 23, 1-24 | 25 |
| 63 | The Effects of Coenzyme Q10 Supplementation on Glucose Metabolism, Lipid Profiles, Inflammation, and Oxidative Stress in Patients With Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. **2018**, 37, 188-193 | 26 |
| 62 | Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. **2018**, 9, 1514 | 80 |
| 61 | Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. **2018**, 2018, 6484839 | 25 |
| 60 | Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients. **2018**, 50, 2073-2079 | 11 |
| 59 | Effect of Coenzyme Q on Insulin Resistance in Korean Patients with Prediabetes: A Pilot Single-Center, Randomized, Double-Blind, Placebo-Controlled Study. **2018**, 2018, 1613247 | 10 |
| 58 | Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial. **2018**, 120, 57-63 | 22 |
| 57 | Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance. **2018**, 7, | 61 |
| 56 | Potential role of coenzyme Q10 in health and disease conditions. **2018**, Volume 10, 1-11 | 20 |
| 55 | Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. **2018**, 105, 992-996 | 15 |
| 54 | CoQ10 a super-vitamin: review on application and biosynthesis. **2018**, 8, 249 | 28 |
| 53 | Coenzyme Q10 suppresses apoptosis of mouse pancreatic □cell line MIN6. **2018**, 10, 47 | 6 |
| 52 | Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. **2019**, 13, 3647-3655 | 9 |
| 51 | Nutrition in the management of type 2 diabetes mellitus: review. **2021**, 127, 509-526 | 2 |

| | | |
|---|---|---|
| 50 | Antihypertensive Potential of Coenzyme Q10 via Free Radical Scavenging and Enhanced Akt-nNOS Signaling in the Nucleus Tractus Solitarii in Rats. **2019**, 63, e1801042 | 5 |
| 49 | Co-production of farnesol and coenzyme Q from metabolically engineered Rhodobacter sphaeroides. **2019**, 18, 98 | 12 |
| 48 | Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview. **2019**, 8, | 22 |
| 47 | Effects of Coenzyme Q10 Supplementation on Serum Adiponectin Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2020**, 15, 3-11 | 1 |
| 46 | Coenzyme Q Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases. **2020**, 21, | 21 |
| 45 | Ubiquinone Supplementation with 300 mg on Glycemic Control and Antioxidant Status in Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial. **2020**, 9, | 1 |
| 44 | Mitoprotective Clinical Strategies in Type 2 Diabetes and Fanconi Anemia Patients: Suggestions for Clinical Management of Mitochondrial Dysfunction. **2020**, 9, | 4 |
| 43 | Coenzyme Q for Patients With Cardiovascular Disease: JACC Focus Seminar. **2021**, 77, 609-619 | 6 |
| 42 | Potential Therapeutic Use of Coenzyme Q10 in Diabetes Mellitus and Its Complications: an Algorithm of Scoping Clinical Review. **2021**, 3, 989-1001 | 1 |
| 41 | Coenzyme Q Biosynthesis Established in the Non-Ubiquinone Containing by Metabolic Engineering. **2021**, 9, 650961 | 4 |
| 40 | Nephroprotective Effect of Coenzyme Q10 alone and in Combination with N-acetylcysteine in Diabetic Nephropathy. **2021**, | |
| 39 | Coenzyme Q and Cardiovascular Diseases. **2021**, 10, | 8 |
| 38 | Enhancement of NADPH availability for coproduction of coenzyme Q and farnesol from Rhodobacter sphaeroides. **2020**, 47, 263-274 | 4 |
| 37 | Mitochondrial Function in Diabetes. **2006**, 221-264 | 1 |
| 36 | Dietary Supplements for Professional Athletes: A Great Potential for Saudi Arabia. **2015**, 3, | 1 |
| 35 | The effects of addition of coenzyme Q10 to metformin on sirolimus-induced diabetes mellitus. **2019**, 34, 365-374 | 8 |
| 34 | Coenzyme Q in Cancer Therapy. **2006**, 2, 290-298 | 2 |
| 33 | Relative Bioavailability of Coenzyme Q10 in Emulsion and Liposome Formulations. **2010**, 18, 99-105 | 6 |

| | | |
|---|---|---|
| 32 | Clinical Trial of the Effects of Coenzyme Q10 Supplementation on Biomarkers of Inflammation and Oxidative Stress in Diabetic Hemodialysis Patients. **2019**, 10, 12 | 11 |
| 31 | Supplements and Foods with Potential Reduction of Blood Pressure in Prehypertensive and Hypertensive Subjects: A Systematic Review. **2013**, 2013, 1-15 | 2 |
| 30 | Coenzyme q10 administration in community-acquired pneumonia in the elderly. **2014**, 16, e18852 | 5 |
| 29 | Oxidative Stress and Glycemic Control in Type 2 Diabetes. **2005**, 345-360 | |
| 28 | The Rational Use of Dietary Supplements, Nutraceuticals, and Functional Foods for the Diabetic and Prediabetic Patient. **2006**, 265-296 | |
| 27 | A Selective Look at Drug Natural Medicine Interactions. **2007**, 1113-1121 | |
| 26 | Diabetes. **2011**, 328-360 | |
| 25 | Hypertension. **2011**, 471-493 | |
| 24 | Coenzyme Q10. **2013**, 675-684 | |
| 23 | Basic Facts about Oxidative Stress, Inflammation, and the Immune System. **2016**, 39-48 | |
| 22 | Coenzyme Q10. **2017**, 59, 63-67 | |
| 21 | Nutritional Influences on Hormonal Health. **2020**, 517-532 | |
| 20 | Coenzyme Q10. **2020**, 526-536.e3 | |
| 19 | Coenzyme Q10: is there a clinical role and a case for measurement?. **2008**, 29, 71-82 | 61 |
| 18 | Naturopathic medicine and type 2 diabetes: a retrospective analysis from an academic clinic. **2006**, 11, 30-9 | 21 |
| 17 | Effects of Coenzyme Q10 Supplementation on Anthropometric Indices in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. **2020**, 11, 181 | |
| 16 | Could nutrient supplements provide additional glycemic control in diabetes management? A systematic review and meta-analysis of randomized controlled trials of as an add-on nutritional supplementation therapy.. **2022**, 45, 185 | 1 |
| 15 | The Effect of Coenzyme Q10/Collagen Hydrogel on Bone Regeneration in Extraction Socket Prior to Implant Placement in Type II Diabetic Patients: A Randomized Controlled Clinical Trial. **2022**, 11, 3059 | 1 |

| | | |
|---|---|---|
| 14 | Preclinical and Clinical Role of Coenzyme Q10 Supplementation in Various Pathological States. | |
| 13 | One-Year Changes in Urinary Microbial Phenolic Metabolites and the Risk of Type 2 Diabetes: A Case-Control Study. **2022**, 11, 1540 | 0 |
| 12 | Rosuvastatin and co-enzyme Q10 improve high-fat and high-fructose diet-induced metabolic syndrome in rats via ameliorating inflammatory and oxidative burden. **2022**, 153, 113526 | 0 |
| 11 | Effects of coenzyme Q10 supplementation on glycemic control: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. **2022**, 52, 101602 | |
| 10 | Dose-response Effect of Coenzyme Q10 Supplementation On Blood Pressure Among Patients With Cardiometabolic Disorders: A GRADE-assessed Systematic Review and Meta-analysis of Randomized Controlled Trials. | 1 |
| 9 | Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial. **2022**, 21, | 1 |
| 8 | Therapeutic Potential of Select Dietary Compounds in the Management of Hypertension and Its Cardiovascular Complications. **2022**, 27, 7222 | 0 |
| 7 | Vitamins, Minerals, Supplements and Dietary Approaches. **2003**, 8, 242-242 | 0 |
| 6 | Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials. | 0 |
| 5 | CoQ Regulates Brown Adipose Tissue Respiration and Uncoupling Protein 1 Expression. **2023**, 12, 14 | 0 |
| 4 | An overview of regulation for nutraceuticals and concept of personalized nutraceuticals. 174113432211508 | 0 |
| 3 | Coenzyme Q10 and Endocrine Disorders: An Overview. **2023**, 12, 514 | 0 |
| 2 | Coenzyme Q10 and N-acetyl cysteine modulates the haematological parameters, markers of oxidative stress and membrane bound phosphatase in spleen toxicity induced by aniline hydrochloride. **2023**, 8, 49-53 | 0 |
| 1 | Effect of Lycopene alone and along with Coenzyme-Q10 in Streptozotocin Induced Peripheral Neuropathy: Biochemical & Behavioural Study. | 0 |